FDA-approval of Cinryze™, Berinert®, Kalbitor®, Firazyr®, and Ruconest® has changed the landscape of HAE therapeutic options in the US.
The variability of HAE, including attack frequency and severity, individual response to therapies, as well as gender, age, other medical conditions and access to medical care, according to Professor Zuraw, highlight the need for a treatment approach uniquely tailored to the needs of each HAE patient. (17)
Browse this page to read much more about treament of HAE.
(1) Zuraw BL. Diagnosis and management of hereditary angioedema: an American approach. Transfus Apher Sci. 2003 Dec;29(3):239-45
(2) Zuraw BL. Current and future therapy for hereditary angioedema. Clinical Immun. 2005;114(12)
(3) Zuraw BL. Hereditary Angioedema. NEJM. 2008;359(10):1029
(4) Farkas H, et. al. The efficacy of short-term danazol prophylaxis in hereditary angioedema patients undergoing maxillofacial and dental procedures. J Oral Maxillofac Surg. 1999 Apr;57(4):404-8
(5) Zuraw BL. HAE therapies, op. cit.
(8) Zuraw BL. Diagnosis, op. cit.
(9) Zuraw BL. HAE therapies, op.cit.
(10) Farkas, op.cit.
(11) Barakat AJ Castaldo AJ. Successful Use of Oxandrolone in the Prophylaxis of Hereditary Angioedema: A Case Report. Pediatric Asthma, Allergy and Immunology. 1999;13(4):189-193
(12) Zuraw, BL. HAE therapies, op. cit.
(13) Bouillet, L. Hereditary angioedema in women. Allergy, Asthma & Clin. Immun. 2010;6(17)
(17) Zuraw, BL. HAE therapies, op.cit.